Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer()

Although immunotherapy continues to demonstrate efficacy in a variety of refractory cancers, currently, no any immunotherapeutic strategy is clinically used for gastric cancer (GC) except its microsatellite instable subtype. Thus, it is important to identify molecular biomarkers for predicting the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zehang, Liu, Zhixian, Li, Mengyuan, Chen, Cai, Wang, Xiaosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078052/
https://www.ncbi.nlm.nih.gov/pubmed/30059832
http://dx.doi.org/10.1016/j.tranon.2018.07.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078052/
https://www.ncbi.nlm.nih.gov/pubmed/30059832
http://dx.doi.org/10.1016/j.tranon.2018.07.012

Ejemplares similares